Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01438177 · OUTCOME

Median Duration of Response of This Regimen

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma · Source last updated 2020-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
up to 2 years

What was measured

Duration of response is the time from response (CR or PR) until progression of disease or relapse. Responses and progression were evaluated based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006).

Analysis population: patients who have responded

Groups in this outcome

Velcade+Cyclophosphamide+Chloroquine

VELCADE given by intravenous push at 1.3 mg/m\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32. Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35. Chloroquine given at 500 mg orally daily on days 1-14 and 22-35. Each cycle is 42 days in length.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Velcade+Cyclophosphamide+Chloroquine9

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Velcade+Cyclophosphamide+Chloroquine4.4Not reported3.98.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.9
        upper Limit
        8.3
        value
        4.4
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
Duration of response is the time from response (CR or PR) until progression of disease or relapse. Responses and progression were evaluated based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006).
dispersion Type
Full Range
groups
  1. description
    VELCADE given by intravenous push at 1.3 mg/m\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32. Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35. Chloroquine given at 500 mg orally daily on days 1-14 and 22-35. Each cycle is 42 days in length.
    id
    OG000
    title
    Velcade+Cyclophosphamide+Chloroquine
param Type
MEDIAN
population Description
patients who have responded
reporting Status
POSTED
time Frame
up to 2 years
title
Median Duration of Response of This Regimen
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice